Bristol myers Squibb Company (BMY) - News Archive

Showing 14 of 14 results.

In a significant stride towards enhancing therapeutic interventions for Small Cell Lung Cancer (SCLC), BioN...

Encouraging Advances and Financial Intricacies of Bristol Myers Squibb and BioNTech s PD-L1xVEGF-A Bispecific Antibody in Small Cell Lung Cancer: A Multifaceted Analysis In a significant stride towards enhancing therape...

Sep 9, 2025 • Major Pharmaceutical Preparations Industry Announcement BioNTech SE

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-gener...

BioNTech and Bristol Myers Squibb Forge Strategic Alliance for Bispecific Antibody Development Amid Competitive Market Pressures MAINZ, Germany, and PRINCETON, USA June 2, 2025 In a significant move that underscores the...

Jun 2, 2025 • Major Pharmaceutical Preparations Industry Partnership BNT327 Co Myers Chancery Court

Harnessing AI to Shape the Future of Therapeutics A Landmark Collaboration between AI Proteins and Bristol Myers Squibb

In a groundbreaking move that promises to reshape the landscape of drug development, AI Proteins, Inc. a pioneer in computational de novo protein design has announced a strategic Research Collaboration and Option Agreem...

Dec 3, 2024 • Major Pharmaceutical Preparations Industry Business Update NYSEFriday Bristol Relay Nearly The Bristol

Bristol Myers Squibb Faces Challenges but Maintains Strong Market Presence

Bristol Myers Squibb Company Shares Face Challenges but Maintain Strong Market PresenceBristol Myers Squibb Company shares have experienced a decline in performance this week, trailing behind the overall market. This dr...

Jul 9, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move Virtual Targeted Protein Degradation Day J Bristo

s with its recent developments, collaborations, and financial performance. The termination of the ADC development deal with Eisai reflects the companys prioritization strategy,...

Exploring Recent Developments and Financial Performance of Bristol Myers Squibb in the Pharmaceutical IndustryIn the fast-paced and ever-evolving pharmaceutical industry, companies constantly strive to develop innovativ...

Jul 3, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move July Open Interest Bristol Myers Squibb Pfizer In

The Resilience of Bristol Myers Squibb A Promising Pharma Stock to Consider

The pharmaceutical industry has always been an attractive investment avenue, with the potential for significant returns. However, not all pharmaceutical companies are created equal. It is crucial for investors to conduc...

Jul 2, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move Below June Bristol Here Bristol Myers Squibb J Bri

Scenic Biotech Partners with Bristol Myers Squibb to Accelerate Drug Target Development

In a bid to expedite the development of drug targets, Scenic Biotech, a pioneer in modifier therapies for severe genetic disorders, has announced a research collaboration with Bristol Myers Squibb (NYSE: BMY). This coll...

Apr 30, 2024 • Major Pharmaceutical Preparations Industry Business Update NYSE

Bristol Myers Squibb and Cellares Enter a $380M Supply Agreement, Bolstering the Manufacture and Access to CAR T Cell Therapies

Revolutionizing the field of immunotherapy, Bristol Myers Squibb and Cellares recently announced their collaborative venture on a worldwide capacity reservation and supply agreement, a business transaction valued at an...

Apr 22, 2024 • Major Pharmaceutical Preparations Industry Business Update NYSE

Bristol Myers Squibb Amplifies Neuroscience Portfolio with Acquisition of Karuna Therapeutics, Spearheading Transformation in Drug Development

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Expands Neuroscience PortfolioPRINCETON, N.J. - In a groundbreaking move, Bristol Myers Squibb (NYSE: BMY) announced today the successful completion of...

Mar 18, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition NYSE

Bristol Myers Squibb's Tender Offer for RayzeBio Expires Amid Challenges in Supplier Revenues and Cost of Sales

Bristol Myers Squibb, a leading global biopharmaceutical company, has announced that its tender offer to acquire all outstanding shares of RayzeBio, Inc. has expired. The company s decision comes as it faces challenges...

Feb 23, 2024 • Major Pharmaceutical Preparations Industry Business Update NYSE

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period in Pursuit of Transformative Merger in the Oncology Sector.

PRINCETON, N.J. & SAN DIEGO - Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) jointly declared today the culmination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 197...

Feb 12, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition NYSE

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology PortfolioPrinceton, New Jersey - Bristol Myers Squibb (NYSE: BMY) has recently announced the successful completi...

Jan 23, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition NYSE

Revolutionary Partnership in Cancer Treatment: Bristol Myers Squibb Collaborates with SystImmune to Bring Promising Therapy to Patients

SystImmune and Bristol Myers Squibb Form Global Partnership for Innovative Cancer TreatmentIn a groundbreaking collaboration, clinical-stage biopharmaceutical company SystImmune and Bristol Myers Squibb (BMY) have joine...

Dec 11, 2023 • Major Pharmaceutical Preparations Industry Product Service News NYSE

Tempus and Bristol Myers Squibb Partner to Revolutionize Cancer Research through AI and Precision Medicine

In a groundbreaking move, Tempus, a leader in artificial intelligence (AI) and precision medicine, has announced a strategic research collaboration with Bristol Myers Squibb (BMY) that aims to accelerate the identificat...

Nov 8, 2023 Contract NYSE